Lisa Cannon
Dentist in Salt Lake City, UT
License number
Utah 6252036-9920
Issued Date
Jun 28, 2006
Expiration Date
May 31, 2018
Category
Dental
Type
Dental Hygienist with Local Anesthesia
Address
Address
Salt Lake City, UT
Education
DIXIE STATE UNIVERSITY
Personal information
See more information about Lisa Cannon at radaris.comName
Address
Phone
4817 S 1115 E, Salt Lake City, UT 84117
560 Division Ln APT B, Salt Lake Cty, UT 84106
560 E Division Ln APT B, Salt Lake City, UT 84106
3711 Little Cottonwood Ln, Sandy, UT 84092
8043 S Jackson Lake Dr, West Jordan, UT 84081
Organization information
See more information about Lisa Cannon at bizstanding.comAlbright Lisa Cannon
4653 Idlewild Rd, Salt Lake City, UT 84124
Industry:
Grant Reviewer
Owner:
Lisa C. Albright (Owner)
Professional information
See more information about Lisa Cannon at trustoria.com
Escrow Officer At Monument Title Insurance
Escrow Officer At Monument Title Insurance
Position:
Escrow Officer at Monument Title Insurance
Location:
Greater Salt Lake City Area
Industry:
Insurance
Work:
Monument Title Insurance
since 2002
-
Escrow Officer
Chromosome 17P-Linked Prostate Cancer Susceptibility Gene
Chromosome 17P-Linked Prostate Cancer Susceptibility Gene
US Patent:
6844189, Jan 18, 2005
Filed:
Nov 5, 1999
Appl. No.:
09/434382
Inventors:
Sean V. Tavtigian - Salt Lake City UT, US
David H.-F. Teng - Salt Lake City UT, US
Jacques Simard - St. Augustin de DesMaures, CA
Johanna M. Rommens - Toronto, CA
Lisa A. Cannon Albright - Salt Lake City UT, US
Susan L. Neuhausen - Salt Lake City UT, US
David H.-F. Teng - Salt Lake City UT, US
Jacques Simard - St. Augustin de DesMaures, CA
Johanna M. Rommens - Toronto, CA
Lisa A. Cannon Albright - Salt Lake City UT, US
Susan L. Neuhausen - Salt Lake City UT, US
Assignee:
Myriad Genetics, Inc. - Salt Lake City UT
University of Utah Research Foundation - Salt Lake City UT
Hospital for Sick Children - Toronto
University of Utah Research Foundation - Salt Lake City UT
Hospital for Sick Children - Toronto
International Classification:
C12N 516, C12N 1512, C12N 1563
US Classification:
435325, 435 691, 435 701, 4353201, 536 231, 536 235
Abstract:
The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect a human prostate cancer predisposing gene (HPC2), some alleles of which cause susceptibility to cancer, in particular prostate cancer. More specifically, the present invention relates to germline mutations in the HPC2 gene and their use in the diagnosis of predisposition to prostate cancer. The invention also relates to presymptomatic therapy of individuals who carry deleterious alleles of the HPC2 gene. The invention further relates to somatic mutations in the HPC2 gene in human prostate cancer and their use in the diagnosis and prognosis of human prostate cancer. Additionally, the invention relates to somatic mutations in the HPC2 gene in other human cancers and their use in the diagnosis and prognosis of human cancers. The invention also relates to the therapy of human cancers which have a mutation in the HPC2 gene, (including gene therapy, protein replacement therapy, protein mimetics, and inhibitors).